Efficacy and safety of sacral nerve root magnetic stimulation combined with solifenacin in female patients with overactive bladder

被引:0
|
作者
Dong, Yan-Qun [1 ]
Wang, Qing [2 ]
Zhang, Li [3 ]
Guo, Ji-Dong [4 ]
Huang, Hui [1 ]
Wu, Jie [5 ]
Tao, Rong-Zhen [2 ]
机构
[1] Nanjing Univ Chinese Med, Dept Gen Surg, Hosp Nanjing 2, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Urol, Affiliated Jiangning Hosp, Nanjing 211100, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Hosp Nanjing 2, Wound Ostomy Nursing Clin, Nanjing, Peoples R China
[4] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China
[5] Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Lab, Nanjing, Jiangsu, Peoples R China
来源
关键词
Overactive bladder; sacral nerve root magnetic stimulation; solifenacin; combination therapy; inconti-; nence; NEUROMODULATION; CONTRACTION; GUIDELINE;
D O I
10.62347/EHTT9544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aimed to assess the efficacy and safety of sacral nerve root magnetic stimulation (SNRMS) combined with solifenacin in female patients with overactive bladder (OAB) symptoms. Methods: A total of 183 female patients with OAB symptoms were prospectively randomized into 2 groups. Ninety-two patients in the combination group accepted SNRMS and solifenacin therapy and 91 patients serving as control accepted only solifenacin therapy. The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQoL), symptom bother score, and overactive bladder syndrome score (OABSS) were compared between the two groups at the end of the second, fourth, and eighth weeks. Results: The incidence of lower urinary tract symptoms, including urgency, frequent urination, and incontinence episodes, was significantly lower in the fourth and eighth weeks in patients of the combination treatment group than those in the solifenacin group (P < 0.05). The incidence of drugrelated adverse events in the two groups was similar, with no statistically significant difference (P > 0.05). The OAB-q HRQoL score in the combination group was significantly higher than that in the solifenacin group between the fourth and eighth weeks (P < 0.05). Meanwhile, the OAB-q symptom bother score and OABSS were both lower in the combination group than those in the solifenacin group from the fourth to eighth weeks (P < 0.05). Conclusions: The combination therapy of SNRMS and solifenacin demonstrated significant improvements over solifenacin monotherapy in reducing OAB symptoms in female patients, providing a higher QoL without increasing bothersome adverse effects.
引用
收藏
页码:685 / 692
页数:8
相关论文
共 50 条
  • [21] Sacral nerve stimulation for the treatment of refractory overactive bladder: preliminary results
    Liu, Z.
    Tian, X.
    Ma, L.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 85 - 86
  • [22] Pudendal nerve stimulation therapy of the overactive bladder -: An alternative to sacral neuromodulation?
    Seif, C
    van der Horst, C
    Naumann, CM
    Jünemann, KP
    Bosch, R
    Buller, J
    Braun, PM
    AKTUELLE UROLOGIE, 2005, 36 (03) : 234 - 238
  • [23] Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder
    Tanaka, Yoshinori
    Masumori, Naoya
    Tsukamoto, Taiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (09) : 796 - 800
  • [24] Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder
    Wang, Jipeng
    Zhou, Zhongbao
    Cui, Yuanshan
    Li, Yongwei
    Yuan, Hejia
    Gao, Zhenli
    Zhu, Zhe
    Wu, Jitao
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 (01) : 22 - 30
  • [25] Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder
    Baron, Maximilien
    Perrouin-Verbe, Marie-Aimee
    Lacombe, Sandy
    Paret, Fanny
    Le Normand, Loic
    Cornu, Jean-Nicolas
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (03) : 1012 - 1019
  • [26] Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment
    Chua, Michael E.
    See, Manuel C.
    Esmena, Ednalyn B.
    Balingit, Jaime C.
    Morales, Marcelino L., Jr.
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2018, 10 (02) : 135 - 142
  • [27] Effect of sacral-root stimulation on the motor cortex in patients with idiopathic overactive bladder syndrome
    Liao, K. K.
    Chen, J. T.
    Lai, K. L.
    Liu, C. Y.
    Lin, C. Y.
    Lin, Y. Y.
    Yu, B. Kj.
    Wu, Z. A.
    NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY, 2008, 38 (01): : 39 - 43
  • [28] Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder
    Newgreen, Donald
    Bosman, Brigitte
    Hollestein-Havelaar, Adriana
    Dahler, Ellen
    Besuyen, Robin
    Snijder, Robert
    Sawyer, Will
    Rittig, Soren
    Bolduc, Stephane
    JOURNAL OF UROLOGY, 2017, 198 (04): : 928 - 936
  • [29] Cost comparison of sacral nerve stimulation and OnabotulinumtoxinA to manage urinary incontinence in patients with overactive bladder
    Loveman, C. L.
    Marsh, R. M.
    Morton, R. M.
    Zeidman, R. Z.
    Ruff, L. R.
    BJU INTERNATIONAL, 2014, 113 : 49 - 49
  • [30] Cost of Neuromodulation Therapies for Overactive Bladder: Percutaneous Tibial Nerve Stimulation Versus Sacral Nerve Stimulation
    Martinson, Melissa
    MacDiarmid, Scott
    Black, Edward
    JOURNAL OF UROLOGY, 2013, 189 (01): : 210 - 216